A proliferation-inducing ligand (APRIL) serum levels predict time to first treatment in patients affected by B-cell chronic lymphocytic leukemia

European Journal of Haematology

Volumn 87, Issue 3, 2011, Pages 228-234

  Tecchio, Cristina ^a   Nichele, Ilaria ^a   Mosna, Federico ^a   Zampieri, Francesca ^a   Leso, Antonella ^a   Al Khaffaf, Ahmad ^a   Veneri, Dino ^a   Andreini, Angelo ^a   Pizzolo, Giovanni ^a   Ambrosetti, Achille ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

A proliferation inducing ligand; B cell chronic lymphocytic leukemia; Time to first treatment

Indexed keywords

APRIL PROTEIN; BETA 2 MICROGLOBULIN; CD38 ANTIGEN; PROTEIN KINASE ZAP 70;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; CANCER RISK; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; DISEASE COURSE; FEMALE; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 84860413100     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01650.x     Document Type: Article

References (28)

1. Hahne M, Kataoka T, Schröter M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 1998;188:1185-90.
2. Dillon S, Gross J, Ansell SM, Novak AJ. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev 2006;5:235-46.
3. Planelles L, Carvalho-Pinto CE, Hardenberg G, et al. APRIL promotes B-1 cell associated neoplasm. Cancer Cell 2004;6:399-408.
4. López-Fraga M, Fernández R, Albar JP, Hahne M. Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase. EMBO Rep 2001;2:945-51.
5. Ingold K, Zumsteg A, Tardivel A, et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005;201:1375-83.
6. Hendriks J, Planelles L, de Jong-Odding J, Hardenberg G, Pals ST, Hahne M, Spaargaren M, Medema JP. Heparan sulphate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Diff 2005;12:637-48.
7. Gupta M, Dillon SR, Ziesmer SC, Feldman AL, Witzig TE, Ansell SM, Cerhan JR, Novak AJ. A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation. Blood 2009;113:5206-16.
8. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A. Lymphoma B Cells Evade Apoptosis through the TNF Family Members BAFF/BLyS and APRIL. J Immunol 2004;172:3268-79.
9. Chiu A, Xu W, He B, et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 2007;109:729-39.
10. Moreaux J, Legouffe E, Jourdan E, Quittet P, Rème T, Lugagne C, Moine P, Rossi JF, Klein B, Tarte K. BAFF and APRIL protect myeloma cells from apoptosis induced by IL-6 deprivation and dexamethasone. Blood 2004;103:3148-57.
11. Schwaller J, Schneider P, Mhawech-Fauceglia P, McKee T, Myit S, Matthes T, Tschopp J, Donze O, Le Gal FA, Huard B. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B cell lymphoma aggressiveness. Blood 2007;109:331-8.
12. Schwaller J, Went P, Matthes T, Dirnhofer S, Donze O, Mhawech-Fauceglia P, Myit S, Huard B. Paracrine promotion of tumor development by the TNF ligand APRIL in Hodgkin's disease. Leukemia 2007;21:1324-7.
13. Endo T, Nishio M, Enzler T, Cottam HB, Fukuda T, James DF, Karin M, Kipps TJ. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood 2007;109:703-10.
14. Ferrer G, Hodgson KE, Abrisqueta P, et al. BAFF and APRIL in chronic lymphocytic leukemia: clinico-biological correlates and prognostic significance. Blood 2009;114:2373.
15. Kern C, Cornuel JF, Billard C, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood 2004;103:679-88.
16. Nishio M, Endo T, Tsukada N, Ohata J, Kitada S, Reed JC, Zvaifler NJ, Kipps TJ. Nurselike cells express BAFF and APRIL which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005;106:1012-20.
17. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7.
18. Hallek M, Cheson BD, Catovsky D, et al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic lymphocytic leukemia updating the National Cancer Institute Working Group 1996 guidelines. Blood 2008;111:5446-56.
19. Delgado J, Pratt G, Phillips N, et al. Beta2-microglobulin is a better indicator of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. Br J Haematol 2009;145:801-5.
20. Zanotti R, Ambrosetti A, Lestani M, et al. ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early phase CLL patients, is a strong adverse prognostic factor. Leukemia 2007;21:102-9.
21. Admirand JH, Knoblock RJ, Coombes KR, et al. Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression. Mod Pathol 2010;23:1518-23.
22. Van Bockstaele F, Verhasselt B, Philippé J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev 2009;23:25-47.
23. Planelles L, Castillo-Gutiérrez S, Medema JP, Morales-Luque A, Merle-Béral H, Hahne M. APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival. Haematologica 2007;92:1284-5.
24. Bojarska-Junak A, Hus I, Chocholska S, Wasik-Szczepanek E, Sieklucka M, Dmoszyńska A, Roliński J. BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features. Leuk Res 2009;33:1319-27.
25. Hallek M, Pfug N. State of the art treatment of chronich lymphocytic leukemia. Blood Rev 2011;25:1-9.
26. Seiffert M, Schulz A, Ohl S, Döhner H, Stilgenbauer S, Lichter P. Soluble CD14 is a novel monocyte-derived survival factor for chronic lymphocytic leukemia cells, which is induced by CLL cells in vitro, and present at abnormally high levels in vivo. Blood 2010;16:4223-330.
27. Ansell SM, Witzig TE, Inwards DJ, et al. Phase I clinical study of Ataciceptin patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Clin Cancer Res 2008;14:1105-10.
28. Kofler DM, Gawlik BB, Elter T, Gianella-Borradori A, Wendtner CM, Hallk M. Final results of a phase Ib trial of Atacicept to neutralize APRIL and BLyS in patients with refractory or relapsed chronic lymphocytic leukemia (CLL). Blood 2009;114:1235.